Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.

Next Previous
Trial Profile

A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Haematological malignancies; Hodgkin's disease; T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Seagen; Seattle Genetics

    • Most Recent Events

    • 28 Jun 2020 An population PK (POPPK) analysis used data from pediatric (NCT01492088) and adult (NCT00430846) studies of brentuximab vedotin to quantify body size effects on ADC exposure; results published in the Journal of Clinical Pharmacology
    • 29 Jan 2018 Results (n=380) of pooled data from six trials assessing population pk and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in ctcl patients, were published in the Clinical Pharmacology and Therapeutics.
    • 12 Jun 2011 Retrospective analysis of two phase I trials, including this trial, presented at the16th Congress of the European Haematology Association (EHA-2011).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top